Pfizer—2023 Call for Independent Quality Improvement Grant Applications Oncology - Prostate Cancer


January 13, 2023

Astellas and Pfizer (collectively, the Companies) are committed to supporting high quality, evidence-based Quality Improvement Grants (QI) that seek to improve the overall safety and quality of patient care and treatment for patients with Prostate Cancer (PC).  

The intent of this QI Call for Grant Applications (CGA) is to encourage the submission of proposals describing concepts and ideas to measurably improve the quality of care for patients with prostate cancer relative to guideline- based management for men with metastatic hormone sensitive prostate cancer (mHSPC) in health systems, cancer care centers, or networks. Proposals that have the most potential to directly impact the quality of care for patients with mHSPC in the US will be prioritized.  

The sustainability and broad applicability of the approach will be key factors in evaluating funded projects. 

Areas of interest can include: 

  • Optimal guideline-based treatment strategies for patients with mHSPC.
  • Delivering optimal treatment wherever there is a point of mHSPC patients contact. 
  • Leveraging a multi-disciplinary team approach to improve patient quality of care. 
  • Therapy management. 
  • Health care professionals, healthcare managers education in terms of clinical and outcomes research in the assessment of treatment options vs healthcare systems sustainability to optimize mHSPC treatment strategies for patients. This can include incorporation of new technologies to enhance the quality of healthcare services delivery to patients with mHSPC 
  • Healthcare provider, patient education, shared treatment goals, and engagement in decision making. 
  • Patient adherence with mHSPC treatments. Submissions addressing topics in addition to those listed above will be considered.  

A plan for long-term sustainability should be included within the submission. 

Deadline: January 13, 2023 

Dollar Amount: $200,000 

Eligibility: Eligible applicants include hospitals, academic medical centers and medical schools, national-level professional medical associations/societies, health systems, cancer care centers or networks. 

Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations are strongly encouraged.  

Please note all partners must have a relevant role and the requesting organization must have a key role in the project. Where a program is offering continuing education credit, the requesting organization must be the accredited grantee. 

Full RFP: https://cdn.pfizer.com/pfizercom/2022-11/GMG_2023-RD-G_FIPGeneTxSitePreparednessQI.pdf?9JMbhNG2nP4nULEoct18QKJ0.j_wFtjb